News & Podcast
Stay up to date with the latest stories, deep-dives and interviews from the Munich startup ecosystem. From funding deals to founder portraits and tech trends.
Rnatics: Hope in pulmonary fibrosis
Rnatics is developing RCS-21, a novel inhalable drug against lung inflammation and idiopathic pulmonary fibrosis. The startup was founded in 2021 as a spin-off from TUM by Stefan Engelhardt together with Thomas Frischmuth and Klaus Rabe. After promising research and ongoing clinical studies, the team aims to reach the next milestones and create new therapy options for patients. Clinical lead and pharmacist with a PhD, Christina Beck, explains the details about the founding and mission to us.
Milestone in treating lung disease? Rnatics secures €2.7 million
The Munich biotech startup Rnatics secures €2.7 million in federal funding. The funds will support clinical development of an inhalable RNA therapeutic for inflammatory and fibrotic lung diseases.